Hulk Hogan's cause of death revealed — wrestling legend had secret health issue
According to the Pinellas County Medical Examiner, Hogan (real name Terry Bollea) died of acute myocardial infarction, also known as a heart attack, on July 24 at his Clearwater, Florida, mansion.
Local police said Hogan suffered a 'cardiac arrest' at his home and was pronounced dead at a nearby hospital.
The cremation summary obtained by Deadline says the WWE icon had a history of atrial fibrillation, a condition characterized by an irregular heart rate, aka AFib.
Fans got wind that Hogan may have been struggling with more serious issues when his ex friend Bubba the Love Sponge blurted out on his radio show the 71-year-old was on his 'death bed' back in June.
'If you did some sniffing around, you might find him in a hospital near you and it's not good,' said the DJ born Todd Clem. 'I got some pretty reliable information [that] there are phone calls being made to various family members about getting to town to come say your goodbyes.'
Hogan's close circle squashed those rumors saying the reason for the Real American Beer founder's recent hospitalizations had to do with surgeries for old ring injuries.
What was not known about Hogan's health and revealed in the new report is he had a history of chronic lymphocytic leukemia (CLL), a blood cancer that starts in the bone marrow, the spongy tissue inside bones where blood cells are made.
As per the Mayo Clinic, this type of leukemia typically progresses slowly. The term 'lymphocytic' comes from the group of white blood cells called lymphocytes, which help the body fight infection. The cause is unknown.
It is unclear when Hogan was diagnosed, what stage of cancer it was or what his treatment entailed.
The American Cancer Society reports that patients aren't necessarily given chemotherapy anymore, but a combination of immunotherapy and targeted drugs.
READ MORE: Brooke Hugan breaks silence on father's death
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Hulk Hogan's Cause of Death Exposed Alongside Hidden Health Battles
Hulk Hogan's Cause of Death Exposed Alongside Hidden Health Battles originally appeared on Men's Fitness. Hulk Hogan's official cause of death has been revealed, as reported by Page Six. Hogan died on July 24 at 71 years old. Reports stated that he had suffered from cardiac arrest at his home in Clearwater, Florida. The outlet confirmed Hogan's cause of death was acute myocardial infarction—a heart attack—which happens when blood flow to the heart is suddenly blocked, leading to damage of the heart tissue. His death was classified as natural, according to a cremation summary approval report released by the Pinellas County Forensic Science Center. "I am not aware when Mr. Bollea will be cremated, only that we received a request for cremation approval," a spokesperson for the medical examiner's office said. Hogan had a medical history that included atrial fibrillation, a condition that causes the heart to beat irregularly and often too quickly. He had also been diagnosed with chronic lymphocytic leukemia, a type of cancer that targets white blood cells called lymphocytes—a detail that doesn't appear to have been publicly a month before his death, Hogan had undergone major spinal fusion surgery, causing the public to speculate about the wrestling legend's health status. Concerns grew after radio host Bubba the Love Sponge claimed a source told him the wrestling legend was bedridden and struggling to speak due to tracheal damage. His wife denied the rumors at the time. "His heart is strong, and there was never any lack of oxygen or brain damage. None of those rumors are true," she wrote on social media. Tributes have been pouring in for Hogan since his passing, with fans, fellow wrestlers, and celebrities honoring his Hogan's Cause of Death Exposed Alongside Hidden Health Battles first appeared on Men's Fitness on Jul 31, 2025 This story was originally reported by Men's Fitness on Jul 31, 2025, where it first appeared.
Business Wire
a day ago
- Business Wire
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis. Enrollment is planned to begin later this year and will include patients with and without atrial fibrillation (AFib). There is a critical need for safe, effective anticoagulants for use in ESKD patients. Tecarfarin's orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. Share Patients with severe kidney disease are already at high risk for thrombotic cardiovascular events such as myocardial infarction and stroke, along with a much greater risk of AFib and venous thromboembolism compared to subjects with normal kidney function. When ESKD patients require dialysis, their transition period comes with even greater risk of myocardial infarction, stroke, and a substantial increase in mortality. 'There is a critical need for safe, effective anticoagulants for use in ESKD patients,' said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. 'Tecarfarin's orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. This study will be an important step forward for the continued development of tecarfarin in ESKD and in other areas with real opportunities to improve patient outcomes with a potentially better vitamin K antagonist.' Currently, there is limited evidence supporting the use of anticoagulant therapy in dialysis patients. Dialysis patients are often excluded from clinical trials due to their high underlying risk profile, and studies of direct oral anticoagulants (DOACs) in this patient population have not provided clear answers. Furthermore, a recent Phase 2 trial of chronic hemodialysis patients sponsored by a global company showed no benefit from the new class of Factor XI inhibitors in maintaining vascular access graft patency. To date, no prospective studies have examined the benefit of oral anticoagulation in preventing thrombotic events at the time of dialysis initiation. 'Initiating dialysis carries substantial excess risk of cardiovascular events and mortality, and to date, this risk has not been sufficiently addressed. Tecarfarin, a next-generation Vitamin K antagonist with a unique metabolism pathway that is not significantly affected by kidney impairment, has potential promise in this area of unmet need,' said Wolfgang Winkelmayer, Professor of Medicine and Chief of Nephrology at Baylor College of Medicine in Houston, Texas. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing transformative therapeutics to address limitations of current anticoagulation therapy specifically. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for several indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of managing Vitamin K antagonists and where DOACs remain inadequate or unproven. Tecarfarin received Orphan Drug Designation (ODD) and fast-track status for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation (ESKD+AFib). The company also received ODD for the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs). The company has submitted an Orphan Drug Designation Request to the US FDA for patients with chronic kidney disease who have an implanted mechanical heart valve (and consequently require lifelong anticoagulation with a VKA) who also have genetic predisposition to impaired CYP2C9 metabolism, and resulting associated challenges with achieving reliable degrees of anticoagulation with the long-term use of warfarin. Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potentially,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding initiation of clinical trial for tecarfarin in patients with ESKD transitioning to dialysis; initiation of registration trial in patients with ESKD and AFib, developing transformative therapeutics to specifically address limitations of current anticoagulation therapy; addressing a critical current treatment gap in patients with ESKD; enrollment in the planned clinical trial beginning later this year; the planned study being an important step forward for the continued development of tecarfarin in ESKD; improving patient outcomes with a potentially better vitamin K antagonist; tecarfarin offering potential promise in patients initiating dialysis; addressing the unmet needs in anticoagulation therapy; and Cadrenal's ability to pursue business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop transformative therapeutics to specifically address limitations of current anticoagulation therapy; the ability to address a critical current treatment gap in patients with ESKD; the ability to advance an innovative solution to address the unmet needs in anticoagulation therapy; the ability to initiate and successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Medscape
2 days ago
- Medscape
Disease Monitoring: Key to Better Leukemia Outcomes?
TOPLINE: Measurable residual disease-guided ibrutinib-venetoclax therapy achieved undetectable disease in bone marrow in 66.2% of patients with chronic lymphocytic leukemia (CLL) within 2 years compared with none with ibrutinib alone and 48.3% with fludarabine, cyclophosphamide, and rituximab (FCR). With a median follow-up of 62.2 months, progression-free survival at 5 years reached 93.9% with ibrutinib-venetoclax vs 79.0% with ibrutinib alone and 58.1% with FCR. METHODOLOGY: A phase 3, multicenter, open-label, parallel-group, randomized, controlled, adaptive trial platform recruited participants from 99 hospitals in the UK. Participants aged 18-75 years with previously untreated CLL or small lymphocytic lymphoma requiring treatment were randomized in a 1:1:1 ratio to receive ibrutinib-venetoclax, ibrutinib alone, or fludarabine-cyclophosphamide-rituximab. Treatment protocols included FCR, repeated every 28 days for six cycles, while ibrutinib was administered orally at 420 mg daily. The ibrutinib-venetoclax group received ibrutinib for 8 weeks before initiating venetoclax, which was administered orally at up to 400 mg daily with incremental dose escalation over 5 weeks. TAKEAWAY: Measurable residual disease was undetectable in bone marrow within 2 years in 66.2% (172/260) of ibrutinib-venetoclax participants compared with none in the ibrutinib-alone group and 48.3% (127/263) in the FCR group (P < .001). Disease progression or death occurred in 6.9% (18/260) of ibrutinib-venetoclax participants vs 22.4% (59/263) in the ibrutinib-alone group (hazard ratio [HR], 0.29; 95% CI, 0.17-0.49; P < .001) and 42.6% (112/263) in the FCR group (HR, 0.13; 95% CI, 0.08-0.21; P < .001). Five-year progression-free survival rates were 93.9% with ibrutinib-venetoclax, 79.0% with ibrutinib alone, and 58.1% with FCR. Death rates were 4.2% (11/260) in the ibrutinib-venetoclax group vs 9.9% (26/263) in the ibrutinib-alone group (HR, 0.41; 95% CI, 0.20-0.83) and 14.8% (39/263) in the FCR group (HR, 0.26; 95% CI, 0.13-0.50). IN PRACTICE: 'Among patients with CLL, undetectable MRD and extended progression-free survival were more common with MRD-guided ibrutinib-venetoclax treatment than with ibrutinib alone or FCR, and the results for overall survival were also consistent with a benefit of MRD-guided ibrutinib-venetoclax (especially among those with unmutated IGHV), findings that support individualized therapy on the basis of response in real time,' wrote the authors of the study. SOURCE: The study was led by researchers from the Leeds Cancer Research UK Clinical Trials Unit at the University of Leeds, with laboratory analysis performed at the Haematological Malignancy Diagnostic Service, St. James's University Hospital in Leeds, England. It was published online on June 15 in The New England Journal of Medicine. LIMITATIONS: According to the authors, the findings should be interpreted in the context of the relatively young trial population, where longer-term follow-up is essential to evaluate the potential for functional cure. DISCLOSURES: The study was supported by grants from Cancer Research UK, with additional unrestricted educational grants from Johnson & Johnson, Pharmacyclics, and AbbVie for trial coordination and laboratory studies. Cancer Research UK also provided a grant for Core Clinical Trials Unit Infrastructure. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
